©2017 by Path Investments.

  • twitter
  • facebook
  • linkedin

Contact US

You have any questions or need to contact us about something? Reach out, we’d be happy to hear from you!

ask.pathinvestments@gmail.com

  • twitter
  • facebook
  • linkedin

All the Latest

Welcome to Path Investments

Please reload

Archive

Please reload

Tags

Our Recent Posts

Please reload

July 7, 2017

PARP inhibitors are a new class of drugs found to suppress the progression of certain cancers such as ovarian, in recurrent platinum-sensitive patients. Due to their initial success in treatment, research and development in the field has taken off and several new drugs have entered the market this year. Given their implications in the field of onco...

April 7, 2017

From the dawn of the Paleolithic era to the present day, humans have carved out the ability to control their surroundings. Switching to agriculture from a hunter-gatherer lifestyle, was one of the many milestones that eventually paved the way for the grand future to come.

During the agricultural revolution, humans began to experiment with techniques...

March 30, 2017

Voclosporin has shown success in its Phase II AURA-LV clinical trials. Phase II results indicated very strong complete remission rates at 24-weeks, surpassing its primary endpoints and a follow-up Phase IIb study demonstrated stronger remission rates at 48-weeks. If AURORA Phase III trials demonstrate as much success as the Phase II trial, Aurinia...

March 29, 2017

In early 2016, global headlines denounced a French clinical trial gone horribly wrong. The study received much media attention after the trial had abruptly concluded with fatal results.  The trial was categorized as a Phase 1 Dose Escalation Study of an Investigational New Drugs effects on the endocannabinoid system.

March 27, 2017

Allergan is an extremely diverse company spanning through many fields of medicine. It is well positioned to keep growing and has a very low single drug risk. Many of its newly introduced drugs are extremely useful to patients especially in the eye care and aesthetics segments and will continue to be adopted thoroughly and quickly. Allergan’s CEO ha...

March 20, 2017

If granted the NDA, Kite will the first to market for this disease and will immediately become a leading treatment option. Given the number of patients living with this disease, many need this drug immediately and will not be able to wait for further results from Juno’s JCAR 017 and potential approval. Kite’s has also raised an additional $409.7 mi...